Varicella zoster virus IgG ELISA
- Regulatory Status
- EU: CE
- Kit size
- 12 x 8
- Method
- ELISA
- Incubation time
- 1 x 1 h, 1 x 30 min, 1 x 15 min
- Standard range
- cut-off index
- Specimen / Volumes
- 10 µL serum, plasma
- Substrate / isotope
- TMB 450 nm
Enzyme immunoassay for the qualitative determination of IgG class antibodies against Varicella zoster virus in human serum or plasma (citrate, heparin). Varicella-Zoster Virus (human herpes virus 3, HHV-3) belongs to the a-subfamily of herpesviridae. The virus particles measure about 145 nm in diameter. They consist of doublestranded DNA, are surrounded by an icosahedral protein capsid and an envelope which contains both host cells and viral components. The virus is usually transmitted in respiratory secretions, and a single serotype causes varicella (Chickenpox), a highly infectious childhood disease, and zoster (shingles), a neurodermic disease; both diseases are found worldwide. Varicella is the acute disease which follows primary contact with the virus, whereas zoster is the response of the partially immune host to a reactivation of the varicella virus present in the body in latent form. Varicella is endemic, most commonly affected are children between 2 and 6 years of age. The course of disease is usually mild and complicated only in immunocompromised children. Rare fatal cases show multiple necrotic lesions in brain, lung (varicella pneumonia), kidneys (hemorrhagic nephritis), spleen, bone marrow, and occasionally in the intestinal tract. The lethality of varicella is below 0.1%. In the infrequent adult infections the disease is more severe, and complications are to be expected in about 5% of all cases. Zoster is of low incidence and appears with increasing frequency and severity with advancing age. Usually the process remains localized, generalization is frequently encountered in a state of immunosuppression. Fatal cases are very rare and nearly always caused by an underlying disease.
Distributed by Tecan, IBL International GmbH.
For concrete data please consult the Instruction for Use in the download box on the top right side.
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).

As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
At Tecan, we are driven to improve people’s lives and health.